
Androgen Receptor
The androgen receptor (AR) is a nuclear hormone receptor that is activated by binding to androgens, such as testosterone and dihydrotestosterone. This receptor plays a crucial role in the development and maintenance of male characteristics, as well as in the regulation of several physiological processes, including muscle growth, libido, and bone density. Androgen receptor inhibitors are widely studied in the context of prostate cancer, where AR signaling is often upregulated. At CymitQuimica, we offer a range of high-quality androgen receptor modulators to support your research in endocrinology, cancer biology, and hormone regulation.
Found 207 products of "Androgen Receptor"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
RU 59063
CAS:<p>RU 59063 is a prototype of a new class of high-affinity nonsteroidal androgen receptor (AR) ligands.</p>Formula:C17H18F3N3O2SPurity:99.09%Color and Shape:SolidMolecular weight:385.4YXG-158
CAS:<p>YXG-158 (Compound 23-h), an orally active androgen receptor (AR) degrader and cytochrome P450 17A1 (CYP17A1) inhibitor, exhibits AR degradation with a DC50 of 1</p>Formula:C30H36FN3OPurity:98%Color and Shape:SolidMolecular weight:473.62Androgen receptor degrader-3
CAS:<p>Androgen Receptor Degrader-3 (ARD-3) is a compound that inhibits androgen receptor signaling and promotes the degradation of the receptor, with potential</p>Formula:C45H51ClN8O5Purity:98%Color and Shape:SolidMolecular weight:819.39EPI-7170
CAS:<p>EPI-7170: Ralaniten analogue, blocks androgen receptor, inhibits transcription in AR & variants, fights enzalutamide-resistant prostate cancer.</p>Formula:C22H28Cl3NO6SColor and Shape:SolidMolecular weight:540.88ID11916
CAS:<p>ID11916 is an orally active compound functioning as both an androgen receptor (AR) antagonist and a phosphodiesterase 5 (PDE5) inhibitor. It disrupts androgen binding to AR, impedes nuclear translocation, and blocks androgen-dependent transcriptional activity of AR, while simultaneously elevating intracellular cGMP levels by inhibiting PKG activation. Moreover, ID11916 exhibits potent anticancer effects in prostate cancer cell lines VCaP and 22Rv1, as well as in AR-positive breast cancer cell line SK-BR-3.</p>Formula:C29H27F3N8O3SColor and Shape:SolidMolecular weight:624.637Androstatrione
CAS:<p>Androstatrione is an androgenic compound.</p>Formula:C19H26O3Color and Shape:SolidMolecular weight:302.41Androgen receptor antagonist 12
CAS:<p>Compound EF2 (Androgen receptor antagonist 12) is an orally active antagonist of the androgen receptor (AR) with an IC50 of 0.30 µM. It inhibits the transcriptional activity of mutant AR and the proliferation of AR-positive PCa (prostate cancer) cell lines. Additionally, Compound EF2 blocks the nuclear translocation of AR and suppresses tumor growth in the C4-2B xenograft mouse model. This compound is used for research in prostate cancer.</p>Formula:C12H8F3N3O2Color and Shape:SolidMolecular weight:283.21SJ1008066
CAS:<p>SJ1008066 is a MAGE-A11 inhibitor with an IC50 of 0.13 μM. It binds to the MAGE homology domain (MHD) and disrupts the MAGE-A11:PCF11 interaction.</p>Formula:C21H22N4Color and Shape:SolidMolecular weight:330.43Androgen receptor antagonist 11
CAS:<p>Androgen receptor antagonist 11 (compound N29) is a selective, orally available antagonist.</p>Formula:C20H19F3N4O3SColor and Shape:SolidMolecular weight:452.45AR/BET protein degrader-1
CAS:<p>AR/BET protein degrader-1 (Compound 149) is a dual-targeting protein degrader of Androgen Receptor and BET (bromodomain and extra-terminal domain), suitable for cancer research.</p>Formula:C43H44N6O5Molecular weight:724.85GLPG0492 (R enantiomer)
CAS:<p>GLPG0492 R enantiomer is the R enantiomer of GLPG-0492, a novel selective androgen receptor modulator.</p>Formula:C19H14F3N3O3Color and Shape:SolidMolecular weight:389.33VNPP433-3β
CAS:<p>VNPP433-3β acts as a molecular glue degrader, targeting the androgen receptor (AR) and its splice variants (AR-Vs) as well as MAP kinase-interacting serine/threonine protein kinase Mnk1/2. It effectively inhibits the proliferation of cancer cells LNCaP, C4-2B, and CWR22Rv1, with GI50 values of 0.2, 0.3, and 0.31 μM, respectively. Additionally, VNPP433-3β shows favorable pharmacokinetics in CD-1 mice and suppresses tumor growth in the CWR22Rv1 xenograft mouse model.</p>Formula:C29H34N4Color and Shape:SolidMolecular weight:438.61AR antagonist 4
<p>AR antagonist 4 (Compound 67-b) is an orally active androgen receptor (AR) antagonist that acts on wild-type AR (IC50: 246.6 nM).</p>Formula:C29H36N4OColor and Shape:SolidMolecular weight:456.62AR antagonist 10
CAS:<p>AR antagonist 10 (Compound Y5) is a potent, orally active androgen receptor (AR) antagonist with an IC50 value of 0.04 μM. It demonstrates a dual mechanism of action: antagonizing AR by disrupting AR dimerization and inducing AR degradation through the ubiquitin-proteasome pathway. This compound shows excellent activity against various resistant AR mutants and effectively inhibits the growth of LNCaP xenograft tumors. AR antagonist 10 is applicable for research in resistant prostate cancer.</p>Formula:C18H17ClN4O3SColor and Shape:SolidMolecular weight:404.871FL442
CAS:<p>FL442 is an Androgen Receptor (AR) modulator. This compound exhibits potent inhibitory effects in AR-dependent prostate cancer cells, showing similar suppression efficiency to the traditional antiandrogen drugs Bicalutamide and Enzalutamide. It also maintains antiandrogen activity against the Enzalutamide-resistant AR mutant F876L. The pharmacokinetic properties of FL442 in mice reveal a longer half-life (8 hours), excellent targeting (prostate tissue), and metabolic stability. Additionally, it is effective at inhibiting LNCaP tumor growth at low plasma concentrations (30 ng/mL).</p>Formula:C15H13F3N2OColor and Shape:SolidMolecular weight:294.27(+)-JJ-74-138
CAS:<p>(+)-JJ-74-138 is a novel non-competitive androgen receptor (AR) antagonist capable of inhibiting enzalutamide-resistant castration-resistant prostate cancer (CRPC).</p>Formula:C22H22F8N2OSColor and Shape:SolidMolecular weight:514.48LX1
CAS:<p>LX1, an anti-prostate cancer compound, specifically targets the androgen receptor (AR), AR variants, and the steroidogenic enzyme AKR1C3. It inhibits AKR1C3's enzymatic function, decreases the conversion of androstenedione to testosterone, and reduces the expression of both AR and AR-V7, subsequently downregulating their target genes. Additionally, LX1 is effective in overcoming tumor cell resistance to Enzalutamide, and when combined with Enzalutamide, it further suppresses tumor growth.</p>Formula:C22H15F6NO2Color and Shape:SolidMolecular weight:439.35Androgen receptor degrader-5
CAS:<p>Androgen receptor degrader-5 (compound 14k) demonstrates superior capabilities, specifically in androgen receptor degradation and antiproliferative activity, showcasing its promising properties.</p>Formula:C29H25F4N5O2Color and Shape:SolidMolecular weight:551.53Androgen receptor ligand 1
CAS:<p>Androgen receptorligand 1 is a ligand for the androgen receptor (AR). It interacts with the CRBN E3 ligase via a linker to form an AR-PROTAC degrader. This compound is useful in prostate cancer research.</p>Formula:C19H16F4N2OColor and Shape:SolidMolecular weight:364.34A4B17
<p>A4B17 is an inhibitor of androgen receptor N-terminal with potential for androgen-responsive prostate cancer treatment.</p>Formula:C14H7F4NSColor and Shape:SolidMolecular weight:297.27

